https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

Long-Acting Injectable Antiretrovirals for PrEP: Will the Tail Wag the Drug? Img

Long-Acting Injectable Antiretrovirals for PrEP: Will the Tail Wag the Drug?

A medicine you get only every two months to reduce your risk of acquiring HIV could be an option in the future, but only if two clinical trials show that it is safe and effective.

This Week in HIV Research: New Maturation Inhibitor May Work Against Protease Inhibitor-Resistant HIV Img

This Week in HIV Research: New Maturation Inhibitor May Work Against Protease Inhibitor-Resistant HIV

This week, a study finds that a new maturation inhibitor in development, GSK3532795, shows activity against HIV that is resistant to protease inhibitors.

The Best HIV Cure Will Be Built With Us, Not Just for Us Img
CROI (Conference on Retroviruses and Opportunistic Infections)

The Best HIV Cure Will Be Built With Us, Not Just for Us

"Without early and consistent partnership with the community in our efforts to incrementally develop a cure for HIV we may never achieve what people with HIV most hope a cure will offer them."

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options

A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...

In the Vanguard of HIV Vaccine Research Img

In the Vanguard of HIV Vaccine Research

An interview with Dan Barouch, M.D., Ph.D., on the key challenges in vaccine development, the pursuit of vaccines to potentially cure HIV and why we should be excited about antibodies.

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART

"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies

Two cohort studies showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.

Dock and Block: Scientists Develop Technique That Makes Cells Resistant to HIV Img

Dock and Block: Scientists Develop Technique That Makes Cells Resistant to HIV

Scientists at The Scripps Research Institute (TSRI) have discovered a way of creating HIV- resistant cells by using antibodies to block HIV directly on the cell surface.

Bictegravir Matches Dolutegravir in HIV Control and Safety Img

Bictegravir Matches Dolutegravir in HIV Control and Safety

Combined with tenofovir alafenamide/emtricitabine (TAF/FTC, Descovy), the investigational HIV integrase inhibitor bictegravir matched the licensed integrase inhibitor dolutegravir (Tivicay, DTG) in viral suppression and safety, according to phase-2 s...